New perspectives on molecular targeted therapy in ovarian clear cell carcinoma |
| |
| Authors: | D S P Tan R E Miller S B Kaye |
| |
| Affiliation: | 1.Cancer Research UK, Professor of Medical Oncology, Drug Development Unit, Royal Marsden NHS Foundation Trust, Section of Medicine, The Institute of Cancer Research, Sycamore House, Downs Road, Sutton SM2 5PT, UK;2.The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK |
| |
| Abstract: | Ovarian clear cell carcinomas (OCCCs) account for about 5–13% of all epithelial ovarian carcinomas in Western populations. It is characterised by resistance to conventional platinum-based chemotherapy, and new therapeutic strategies are urgently required. This article will focus on how recent discoveries have enhanced our understanding of the molecular pathogenesis of OCCCs, leading to new therapeutic opportunities. These include mutations in ARID1A, which provides a link to endometriosis, upregulation of the phosphatidylinositol 3-kinase/AKT pathway, particularly through mutations of PIK3CA and inactivation of PTEN, and increased activity of pathways involved in angiogenesis. Targeting HER2, apoptotic escape mechanisms and mismatch repair defects offer additional opportunities for treating this enigmatic tumour subtype. |
| |
| Keywords: | ovarian clear cell carcinoma molecular targeted therapy |
|
|
